Oral Antidiabetic Agents View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-02

AUTHORS

Andrew J. Krentz, Clifford J. Bailey

ABSTRACT

Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term. The majority of patients are overweight or obese at diagnosis and will be unable to achieve or sustain near normoglycaemia without oral antidiabetic agents; a sizeable proportion of patients will eventually require insulin therapy to maintain long-term glycaemic control, either as monotherapy or in conjunction with oral antidiabetic therapy. The frequent need for escalating therapy is held to reflect progressive loss of islet beta-cell function, usually in the presence of obesity-related insulin resistance. Today's clinicians are presented with an extensive range of oral antidiabetic drugs for type 2 diabetes. The main classes are heterogeneous in their modes of action, safety profiles and tolerability. These main classes include agents that stimulate insulin secretion (sulphonylureas and rapid-acting secretagogues), reduce hepatic glucose production (biguanides), delay digestion and absorption of intestinal carbohydrate (alpha-glucosidase inhibitors) or improve insulin action (thiazolidinediones). The UKPDS (United Kingdom Prospective Diabetes Study) demonstrated the benefits of intensified glycaemic control on microvascular complications in newly diagnosed patients with type 2 diabetes. However, the picture was less clearcut with regard to macrovascular disease, with neither sulphonylureas nor insulin significantly reducing cardiovascular events. The impact of oral antidiabetic agents on atherosclerosis--beyond expected effects on glycaemic control--is an increasingly important consideration. In the UKPDS, overweight and obese patients randomised to initial monotherapy with metformin experienced significant reductions in myocardial infarction and diabetes-related deaths. Metformin does not promote weight gain and has beneficial effects on several cardiovascular risk factors. Accordingly, metformin is widely regarded as the drug of choice for most patients with type 2 diabetes. Concern about cardiovascular safety of sulphonylureas has largely dissipated with generally reassuring results from clinical trials, including the UKPDS. Encouragingly, the recent Steno-2 Study showed that intensive target-driven, multifactorial approach to management, based around a sulphonylurea, reduced the risk of both micro- and macrovascular complications in high-risk patients. Theoretical advantages of selectively targeting postprandial hyperglycaemia require confirmation in clinical trials of drugs with preferential effects on this facet of hyperglycaemia are currently in progress. The insulin-sensitising thiazolidinedione class of antidiabetic agents has potentially advantageous effects on multiple components of the metabolic syndrome; the results of clinical trials with cardiovascular endpoints are awaited. The selection of initial monotherapy is based on a clinical and biochemical assessment of the patient, safety considerations being paramount. In some circumstances, for example pregnancy or severe hepatic or renal impairment, insulin may be the treatment of choice when nonpharmacological measures prove inadequate. Insulin is also required for metabolic decompensation, that is, incipient or actual diabetic ketoacidosis, or non-ketotic hyperosmolar hyperglycaemia. Certain comorbidities, for example presentation with myocardial infarction during other acute intercurrent illness, may make insulin the best option. Oral antidiabetic agents should be initiated at a low dose and titrated up according to glycaemic response, as judged by measurement of glycosylated haemoglobin (HbA1c) concentration, supplemented in some patients by self monitoring of capillary blood glucose. The average glucose-lowering effect of the major classes of oral antidiabetic agents is broadly similar (averaging a 1-2% reduction in HbA1c), alpha-glucosidase inhibitors being rather less effective. Tailoring the treatment to the individual patient is an important principle. Doses are gradually titrated up according to response. However, the maximal glucose-lowering action for sulphonylureas is usually attained at appreciably lower doses (approximately 50%) than the manufacturers' recommended daily maximum. Combinations of certain agents, for example a secretagogue plus a biguanide or a thiazolidinedione, are logical and widely used, and combination preparations are now available in some countries. While the benefits of metformin added to a sulphonylurea were initially less favourable in the UKPDS, longer-term data have allayed concern. When considering long-term therapy, issues such as tolerability and convenience are important additional considerations. Neither sulphonylureas nor biguanides are able to appreciably alter the rate of progression of hyperglycaemia in patients with type 2 diabetes. Preliminary data suggesting that thiazolidinediones may provide better long-term glycaemic stability are currently being tested in clinical trials; current evidence, while encouraging, is not conclusive. Delayed progression from glucose intolerance to type 2 diabetes in high-risk individuals with glucose intolerance has been demonstrated with troglitazone, metformin and acarbose. However, intensive lifestyle intervention can be more effective than drug therapy, at least in the setting of interventional clinical trials. No antidiabetic drugs are presently licensed for use in prediabetic individuals. More... »

PAGES

385-411

Identifiers

URI

http://scigraph.springernature.com/pub.10.2165/00003495-200565030-00005

DOI

http://dx.doi.org/10.2165/00003495-200565030-00005

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1020874837

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15669880


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biguanides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycoside Hydrolase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sulfonylurea Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thiazolidinediones", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University Hospital Southampton NHS Foundation Trust", 
          "id": "https://www.grid.ac/institutes/grid.430506.4", 
          "name": [
            "Southampton University Hospitals NHS Trust, Southampton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Krentz", 
        "givenName": "Andrew J.", 
        "id": "sg:person.0676605226.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676605226.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aston University", 
          "id": "https://www.grid.ac/institutes/grid.7273.1", 
          "name": [
            "Life and Health Sciences, Aston Pharmacy School, Aston University, Birmingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bailey", 
        "givenName": "Clifford J.", 
        "id": "sg:person.01012617522.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012617522.23"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1001/jama.281.21.2005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000047333"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/14746514030030051001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000069406"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/14746514030030051001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000069406"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.amjmed.2003.08.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000975444"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa012512", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001036745"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1464-5491.1999.00166.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001335743"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.327.7421.951", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002098315"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.325.7369.860", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002420008"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200060050-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003434116", 
          "https://doi.org/10.2165/00003495-200060050-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200060050-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003434116", 
          "https://doi.org/10.2165/00003495-200060050-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7861/clinmedicine.1-6-472", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003704904"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00041433-200312000-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003768084"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00041433-200312000-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003768084"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/00041433-200312000-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003768084"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200464120-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005716893", 
          "https://doi.org/10.2165/00003495-200464120-00006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200464120-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005716893", 
          "https://doi.org/10.2165/00003495-200464120-00006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.0000103683.99399.7e", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007027759"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-003-1153-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007171833", 
          "https://doi.org/10.1007/s00125-003-1153-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-003-1153-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007171833", 
          "https://doi.org/10.1007/s00125-003-1153-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002512-200017050-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008294814", 
          "https://doi.org/10.2165/00002512-200017050-00007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002512-200017050-00007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008294814", 
          "https://doi.org/10.2165/00002512-200017050-00007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diabetes.51.9.2796", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011011786"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200262100-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012559787", 
          "https://doi.org/10.2165/00003495-200262100-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200262100-00004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012559787", 
          "https://doi.org/10.2165/00003495-200262100-00004"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.r100034200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014264954"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(01)06715-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014936450"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(98)07037-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015697368"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa021778", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018344641"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1463-1326.2000.00053.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018580225"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(98)07019-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018881858"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1463-1326.2002.00189.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019630371"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmra041001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019925590"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.287.19.2570", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023285132"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0531-5131(02)01278-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023539162"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0531-5131(02)01278-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023539162"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2362.2004.01381.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025780657"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002018-199411040-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026564315", 
          "https://doi.org/10.2165/00002018-199411040-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(00)90002-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031243451"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199602293340906", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031600279"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1042/bst0300333", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031790720"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1042/bst0300333", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031790720"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1464-5491.2002.00734.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033160698"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.24.4.758", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035419921"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/3-540-29832-0_122", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037474338", 
          "https://doi.org/10.1007/3-540-29832-0_122"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-002-0932-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037610401", 
          "https://doi.org/10.1007/s00125-002-0932-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-002-0932-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037610401", 
          "https://doi.org/10.1007/s00125-002-0932-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(02)08905-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040832542"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.290.4.486", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042599369"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2125.1999.00030.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043231388"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0735-1097(03)00916-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043406867"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0735-1097(03)00916-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043406867"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci13505", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043705336"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci13505", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043705336"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002512-200118050-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044292364", 
          "https://doi.org/10.2165/00002512-200118050-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00002512-200118050-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044292364", 
          "https://doi.org/10.2165/00002512-200118050-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1074/jbc.m106424200", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045195003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci10762", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045265009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.287.3.360", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045284159"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001250051247", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046239186", 
          "https://doi.org/10.1007/s001250051247"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s001250051247", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046239186", 
          "https://doi.org/10.1007/s001250051247"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.25.12.2244", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047089706"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.321.7256.252", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048879453"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1515/jpem.2002.15.s2.737", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049225232"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1464-5491.1999.00023.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049451052"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-003-1228-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050026340", 
          "https://doi.org/10.1007/s00125-003-1228-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-003-1228-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050026340", 
          "https://doi.org/10.1007/s00125-003-1228-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200363100-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050165822", 
          "https://doi.org/10.2165/00003495-200363100-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003495-200363100-00002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050165822", 
          "https://doi.org/10.2165/00003495-200363100-00002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.amjmed.2003.10.017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051876972"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.321.7258.394", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052043497"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.21.9.976", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070732325"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diab.37.12.1595", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070735404"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diabetes.37.12.1595", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070741229"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.15.6.737", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070745704"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.16.1.184", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070745798"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.20.6.925", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070747742"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2337/diacare.22.6.960", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1070748809"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-131-4-199908170-00008", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073703508"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-134-1-200101020-00014", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073704512"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-137-1-200207020-00009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073705509"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1152/ajpendo.1999.277.1.e1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074492025"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-02", 
    "datePublishedReg": "2005-02-01", 
    "description": "Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term. The majority of patients are overweight or obese at diagnosis and will be unable to achieve or sustain near normoglycaemia without oral antidiabetic agents; a sizeable proportion of patients will eventually require insulin therapy to maintain long-term glycaemic control, either as monotherapy or in conjunction with oral antidiabetic therapy. The frequent need for escalating therapy is held to reflect progressive loss of islet beta-cell function, usually in the presence of obesity-related insulin resistance. Today's clinicians are presented with an extensive range of oral antidiabetic drugs for type 2 diabetes. The main classes are heterogeneous in their modes of action, safety profiles and tolerability. These main classes include agents that stimulate insulin secretion (sulphonylureas and rapid-acting secretagogues), reduce hepatic glucose production (biguanides), delay digestion and absorption of intestinal carbohydrate (alpha-glucosidase inhibitors) or improve insulin action (thiazolidinediones). The UKPDS (United Kingdom Prospective Diabetes Study) demonstrated the benefits of intensified glycaemic control on microvascular complications in newly diagnosed patients with type 2 diabetes. However, the picture was less clearcut with regard to macrovascular disease, with neither sulphonylureas nor insulin significantly reducing cardiovascular events. The impact of oral antidiabetic agents on atherosclerosis--beyond expected effects on glycaemic control--is an increasingly important consideration. In the UKPDS, overweight and obese patients randomised to initial monotherapy with metformin experienced significant reductions in myocardial infarction and diabetes-related deaths. Metformin does not promote weight gain and has beneficial effects on several cardiovascular risk factors. Accordingly, metformin is widely regarded as the drug of choice for most patients with type 2 diabetes. Concern about cardiovascular safety of sulphonylureas has largely dissipated with generally reassuring results from clinical trials, including the UKPDS. Encouragingly, the recent Steno-2 Study showed that intensive target-driven, multifactorial approach to management, based around a sulphonylurea, reduced the risk of both micro- and macrovascular complications in high-risk patients. Theoretical advantages of selectively targeting postprandial hyperglycaemia require confirmation in clinical trials of drugs with preferential effects on this facet of hyperglycaemia are currently in progress. The insulin-sensitising thiazolidinedione class of antidiabetic agents has potentially advantageous effects on multiple components of the metabolic syndrome; the results of clinical trials with cardiovascular endpoints are awaited. The selection of initial monotherapy is based on a clinical and biochemical assessment of the patient, safety considerations being paramount. In some circumstances, for example pregnancy or severe hepatic or renal impairment, insulin may be the treatment of choice when nonpharmacological measures prove inadequate. Insulin is also required for metabolic decompensation, that is, incipient or actual diabetic ketoacidosis, or non-ketotic hyperosmolar hyperglycaemia. Certain comorbidities, for example presentation with myocardial infarction during other acute intercurrent illness, may make insulin the best option. Oral antidiabetic agents should be initiated at a low dose and titrated up according to glycaemic response, as judged by measurement of glycosylated haemoglobin (HbA1c) concentration, supplemented in some patients by self monitoring of capillary blood glucose. The average glucose-lowering effect of the major classes of oral antidiabetic agents is broadly similar (averaging a 1-2% reduction in HbA1c), alpha-glucosidase inhibitors being rather less effective. Tailoring the treatment to the individual patient is an important principle. Doses are gradually titrated up according to response. However, the maximal glucose-lowering action for sulphonylureas is usually attained at appreciably lower doses (approximately 50%) than the manufacturers' recommended daily maximum. Combinations of certain agents, for example a secretagogue plus a biguanide or a thiazolidinedione, are logical and widely used, and combination preparations are now available in some countries. While the benefits of metformin added to a sulphonylurea were initially less favourable in the UKPDS, longer-term data have allayed concern. When considering long-term therapy, issues such as tolerability and convenience are important additional considerations. Neither sulphonylureas nor biguanides are able to appreciably alter the rate of progression of hyperglycaemia in patients with type 2 diabetes. Preliminary data suggesting that thiazolidinediones may provide better long-term glycaemic stability are currently being tested in clinical trials; current evidence, while encouraging, is not conclusive. Delayed progression from glucose intolerance to type 2 diabetes in high-risk individuals with glucose intolerance has been demonstrated with troglitazone, metformin and acarbose. However, intensive lifestyle intervention can be more effective than drug therapy, at least in the setting of interventional clinical trials. No antidiabetic drugs are presently licensed for use in prediabetic individuals.", 
    "genre": "research_article", 
    "id": "sg:pub.10.2165/00003495-200565030-00005", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1084788", 
        "issn": [
          "0012-6667", 
          "1179-1950"
        ], 
        "name": "Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "65"
      }
    ], 
    "name": "Oral Antidiabetic Agents", 
    "pagination": "385-411", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "6375df6f71f55c06beb95c3ae0fb82945e4be609268fe9352eba8dbfd4e50c45"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15669880"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7600076"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.2165/00003495-200565030-00005"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1020874837"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.2165/00003495-200565030-00005", 
      "https://app.dimensions.ai/details/publication/pub.1020874837"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:43", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000363_0000000363/records_70066_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.2165/00003495-200565030-00005"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00003495-200565030-00005'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00003495-200565030-00005'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00003495-200565030-00005'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00003495-200565030-00005'


 

This table displays all metadata directly associated to this object as RDF triples.

315 TRIPLES      21 PREDICATES      101 URIs      29 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.2165/00003495-200565030-00005 schema:about N03e359da35224ff688dc3928ec88dc3e
2 N4430e3f309494478bbaa17169acdb09b
3 N59c91183256c4761bbdeea5d77002e1f
4 N5a327c543c934f90b96203f8fa1efcbf
5 N767be231d2264b3c9ff73cd5c8e36809
6 Nc9199ea1bb85455caaa13042639a81a0
7 Ncdfd5b110aaf4692a2b9a01bd9a59624
8 Ndfc61b193e304fb8bcd1a883794c60aa
9 anzsrc-for:11
10 anzsrc-for:1103
11 schema:author Ncd8f42fa26e547ee85791717390cddfd
12 schema:citation sg:pub.10.1007/3-540-29832-0_122
13 sg:pub.10.1007/s00125-002-0932-4
14 sg:pub.10.1007/s00125-003-1153-1
15 sg:pub.10.1007/s00125-003-1228-z
16 sg:pub.10.1007/s001250051247
17 sg:pub.10.2165/00002018-199411040-00002
18 sg:pub.10.2165/00002512-200017050-00007
19 sg:pub.10.2165/00002512-200118050-00003
20 sg:pub.10.2165/00003495-200060050-00004
21 sg:pub.10.2165/00003495-200262100-00004
22 sg:pub.10.2165/00003495-200363100-00002
23 sg:pub.10.2165/00003495-200464120-00006
24 https://doi.org/10.1001/jama.281.21.2005
25 https://doi.org/10.1001/jama.287.19.2570
26 https://doi.org/10.1001/jama.287.3.360
27 https://doi.org/10.1001/jama.290.4.486
28 https://doi.org/10.1016/j.amjmed.2003.08.010
29 https://doi.org/10.1016/j.amjmed.2003.10.017
30 https://doi.org/10.1016/s0140-6736(00)90002-3
31 https://doi.org/10.1016/s0140-6736(01)06715-0
32 https://doi.org/10.1016/s0140-6736(02)08905-5
33 https://doi.org/10.1016/s0140-6736(98)07019-6
34 https://doi.org/10.1016/s0140-6736(98)07037-8
35 https://doi.org/10.1016/s0531-5131(02)01278-5
36 https://doi.org/10.1016/s0735-1097(03)00916-1
37 https://doi.org/10.1042/bst0300333
38 https://doi.org/10.1046/j.1365-2125.1999.00030.x
39 https://doi.org/10.1046/j.1463-1326.2000.00053.x
40 https://doi.org/10.1046/j.1463-1326.2002.00189.x
41 https://doi.org/10.1046/j.1464-5491.1999.00023.x
42 https://doi.org/10.1046/j.1464-5491.1999.00166.x
43 https://doi.org/10.1046/j.1464-5491.2002.00734.x
44 https://doi.org/10.1056/nejm199602293340906
45 https://doi.org/10.1056/nejmoa012512
46 https://doi.org/10.1056/nejmoa021778
47 https://doi.org/10.1056/nejmra041001
48 https://doi.org/10.1074/jbc.m106424200
49 https://doi.org/10.1074/jbc.r100034200
50 https://doi.org/10.1097/00041433-200312000-00004
51 https://doi.org/10.1111/j.1365-2362.2004.01381.x
52 https://doi.org/10.1136/bmj.321.7256.252
53 https://doi.org/10.1136/bmj.321.7258.394
54 https://doi.org/10.1136/bmj.325.7369.860
55 https://doi.org/10.1136/bmj.327.7421.951
56 https://doi.org/10.1152/ajpendo.1999.277.1.e1
57 https://doi.org/10.1161/01.cir.0000103683.99399.7e
58 https://doi.org/10.1172/jci10762
59 https://doi.org/10.1172/jci13505
60 https://doi.org/10.1177/14746514030030051001
61 https://doi.org/10.1515/jpem.2002.15.s2.737
62 https://doi.org/10.2337/diab.21.9.976
63 https://doi.org/10.2337/diab.37.12.1595
64 https://doi.org/10.2337/diabetes.37.12.1595
65 https://doi.org/10.2337/diabetes.51.9.2796
66 https://doi.org/10.2337/diacare.15.6.737
67 https://doi.org/10.2337/diacare.16.1.184
68 https://doi.org/10.2337/diacare.20.6.925
69 https://doi.org/10.2337/diacare.22.6.960
70 https://doi.org/10.2337/diacare.24.4.758
71 https://doi.org/10.2337/diacare.25.12.2244
72 https://doi.org/10.7326/0003-4819-131-4-199908170-00008
73 https://doi.org/10.7326/0003-4819-134-1-200101020-00014
74 https://doi.org/10.7326/0003-4819-137-1-200207020-00009
75 https://doi.org/10.7861/clinmedicine.1-6-472
76 schema:datePublished 2005-02
77 schema:datePublishedReg 2005-02-01
78 schema:description Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term. The majority of patients are overweight or obese at diagnosis and will be unable to achieve or sustain near normoglycaemia without oral antidiabetic agents; a sizeable proportion of patients will eventually require insulin therapy to maintain long-term glycaemic control, either as monotherapy or in conjunction with oral antidiabetic therapy. The frequent need for escalating therapy is held to reflect progressive loss of islet beta-cell function, usually in the presence of obesity-related insulin resistance. Today's clinicians are presented with an extensive range of oral antidiabetic drugs for type 2 diabetes. The main classes are heterogeneous in their modes of action, safety profiles and tolerability. These main classes include agents that stimulate insulin secretion (sulphonylureas and rapid-acting secretagogues), reduce hepatic glucose production (biguanides), delay digestion and absorption of intestinal carbohydrate (alpha-glucosidase inhibitors) or improve insulin action (thiazolidinediones). The UKPDS (United Kingdom Prospective Diabetes Study) demonstrated the benefits of intensified glycaemic control on microvascular complications in newly diagnosed patients with type 2 diabetes. However, the picture was less clearcut with regard to macrovascular disease, with neither sulphonylureas nor insulin significantly reducing cardiovascular events. The impact of oral antidiabetic agents on atherosclerosis--beyond expected effects on glycaemic control--is an increasingly important consideration. In the UKPDS, overweight and obese patients randomised to initial monotherapy with metformin experienced significant reductions in myocardial infarction and diabetes-related deaths. Metformin does not promote weight gain and has beneficial effects on several cardiovascular risk factors. Accordingly, metformin is widely regarded as the drug of choice for most patients with type 2 diabetes. Concern about cardiovascular safety of sulphonylureas has largely dissipated with generally reassuring results from clinical trials, including the UKPDS. Encouragingly, the recent Steno-2 Study showed that intensive target-driven, multifactorial approach to management, based around a sulphonylurea, reduced the risk of both micro- and macrovascular complications in high-risk patients. Theoretical advantages of selectively targeting postprandial hyperglycaemia require confirmation in clinical trials of drugs with preferential effects on this facet of hyperglycaemia are currently in progress. The insulin-sensitising thiazolidinedione class of antidiabetic agents has potentially advantageous effects on multiple components of the metabolic syndrome; the results of clinical trials with cardiovascular endpoints are awaited. The selection of initial monotherapy is based on a clinical and biochemical assessment of the patient, safety considerations being paramount. In some circumstances, for example pregnancy or severe hepatic or renal impairment, insulin may be the treatment of choice when nonpharmacological measures prove inadequate. Insulin is also required for metabolic decompensation, that is, incipient or actual diabetic ketoacidosis, or non-ketotic hyperosmolar hyperglycaemia. Certain comorbidities, for example presentation with myocardial infarction during other acute intercurrent illness, may make insulin the best option. Oral antidiabetic agents should be initiated at a low dose and titrated up according to glycaemic response, as judged by measurement of glycosylated haemoglobin (HbA1c) concentration, supplemented in some patients by self monitoring of capillary blood glucose. The average glucose-lowering effect of the major classes of oral antidiabetic agents is broadly similar (averaging a 1-2% reduction in HbA1c), alpha-glucosidase inhibitors being rather less effective. Tailoring the treatment to the individual patient is an important principle. Doses are gradually titrated up according to response. However, the maximal glucose-lowering action for sulphonylureas is usually attained at appreciably lower doses (approximately 50%) than the manufacturers' recommended daily maximum. Combinations of certain agents, for example a secretagogue plus a biguanide or a thiazolidinedione, are logical and widely used, and combination preparations are now available in some countries. While the benefits of metformin added to a sulphonylurea were initially less favourable in the UKPDS, longer-term data have allayed concern. When considering long-term therapy, issues such as tolerability and convenience are important additional considerations. Neither sulphonylureas nor biguanides are able to appreciably alter the rate of progression of hyperglycaemia in patients with type 2 diabetes. Preliminary data suggesting that thiazolidinediones may provide better long-term glycaemic stability are currently being tested in clinical trials; current evidence, while encouraging, is not conclusive. Delayed progression from glucose intolerance to type 2 diabetes in high-risk individuals with glucose intolerance has been demonstrated with troglitazone, metformin and acarbose. However, intensive lifestyle intervention can be more effective than drug therapy, at least in the setting of interventional clinical trials. No antidiabetic drugs are presently licensed for use in prediabetic individuals.
79 schema:genre research_article
80 schema:inLanguage en
81 schema:isAccessibleForFree false
82 schema:isPartOf Na103e70b6f09479884d723bb4feb0508
83 Nf634e63cb6a64e48af1ae0dee3c2db55
84 sg:journal.1084788
85 schema:name Oral Antidiabetic Agents
86 schema:pagination 385-411
87 schema:productId N33fcfb3a51814d7e896efcf1a4387a9d
88 N5ba96dbd540344178e2095454ed72b79
89 Na743b52d1e4a4a36a10a87e3620ffa84
90 Nc339bed7ebca419cb8ce8cf9d4d850b8
91 Ndad6600ae2dd45adbf6a00fd901d8b75
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020874837
93 https://doi.org/10.2165/00003495-200565030-00005
94 schema:sdDatePublished 2019-04-11T12:43
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher Nd10b1adf2d624b7a95169ee7e2b33a15
97 schema:url http://link.springer.com/10.2165/00003495-200565030-00005
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N03e359da35224ff688dc3928ec88dc3e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Diabetes Mellitus, Type 2
103 rdf:type schema:DefinedTerm
104 N33fcfb3a51814d7e896efcf1a4387a9d schema:name readcube_id
105 schema:value 6375df6f71f55c06beb95c3ae0fb82945e4be609268fe9352eba8dbfd4e50c45
106 rdf:type schema:PropertyValue
107 N4430e3f309494478bbaa17169acdb09b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Sulfonylurea Compounds
109 rdf:type schema:DefinedTerm
110 N59c91183256c4761bbdeea5d77002e1f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Biguanides
112 rdf:type schema:DefinedTerm
113 N5a327c543c934f90b96203f8fa1efcbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Glycoside Hydrolase Inhibitors
115 rdf:type schema:DefinedTerm
116 N5ba96dbd540344178e2095454ed72b79 schema:name pubmed_id
117 schema:value 15669880
118 rdf:type schema:PropertyValue
119 N767be231d2264b3c9ff73cd5c8e36809 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Thiazolidinediones
121 rdf:type schema:DefinedTerm
122 Na103e70b6f09479884d723bb4feb0508 schema:issueNumber 3
123 rdf:type schema:PublicationIssue
124 Na595feca509741d388100b27a8857a1c rdf:first sg:person.01012617522.23
125 rdf:rest rdf:nil
126 Na743b52d1e4a4a36a10a87e3620ffa84 schema:name doi
127 schema:value 10.2165/00003495-200565030-00005
128 rdf:type schema:PropertyValue
129 Nc339bed7ebca419cb8ce8cf9d4d850b8 schema:name nlm_unique_id
130 schema:value 7600076
131 rdf:type schema:PropertyValue
132 Nc9199ea1bb85455caaa13042639a81a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Hypoglycemic Agents
134 rdf:type schema:DefinedTerm
135 Ncd8f42fa26e547ee85791717390cddfd rdf:first sg:person.0676605226.07
136 rdf:rest Na595feca509741d388100b27a8857a1c
137 Ncdfd5b110aaf4692a2b9a01bd9a59624 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Humans
139 rdf:type schema:DefinedTerm
140 Nd10b1adf2d624b7a95169ee7e2b33a15 schema:name Springer Nature - SN SciGraph project
141 rdf:type schema:Organization
142 Ndad6600ae2dd45adbf6a00fd901d8b75 schema:name dimensions_id
143 schema:value pub.1020874837
144 rdf:type schema:PropertyValue
145 Ndfc61b193e304fb8bcd1a883794c60aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Randomized Controlled Trials as Topic
147 rdf:type schema:DefinedTerm
148 Nf634e63cb6a64e48af1ae0dee3c2db55 schema:volumeNumber 65
149 rdf:type schema:PublicationVolume
150 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
151 schema:name Medical and Health Sciences
152 rdf:type schema:DefinedTerm
153 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
154 schema:name Clinical Sciences
155 rdf:type schema:DefinedTerm
156 sg:journal.1084788 schema:issn 0012-6667
157 1179-1950
158 schema:name Drugs
159 rdf:type schema:Periodical
160 sg:person.01012617522.23 schema:affiliation https://www.grid.ac/institutes/grid.7273.1
161 schema:familyName Bailey
162 schema:givenName Clifford J.
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012617522.23
164 rdf:type schema:Person
165 sg:person.0676605226.07 schema:affiliation https://www.grid.ac/institutes/grid.430506.4
166 schema:familyName Krentz
167 schema:givenName Andrew J.
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676605226.07
169 rdf:type schema:Person
170 sg:pub.10.1007/3-540-29832-0_122 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037474338
171 https://doi.org/10.1007/3-540-29832-0_122
172 rdf:type schema:CreativeWork
173 sg:pub.10.1007/s00125-002-0932-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037610401
174 https://doi.org/10.1007/s00125-002-0932-4
175 rdf:type schema:CreativeWork
176 sg:pub.10.1007/s00125-003-1153-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007171833
177 https://doi.org/10.1007/s00125-003-1153-1
178 rdf:type schema:CreativeWork
179 sg:pub.10.1007/s00125-003-1228-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1050026340
180 https://doi.org/10.1007/s00125-003-1228-z
181 rdf:type schema:CreativeWork
182 sg:pub.10.1007/s001250051247 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046239186
183 https://doi.org/10.1007/s001250051247
184 rdf:type schema:CreativeWork
185 sg:pub.10.2165/00002018-199411040-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026564315
186 https://doi.org/10.2165/00002018-199411040-00002
187 rdf:type schema:CreativeWork
188 sg:pub.10.2165/00002512-200017050-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008294814
189 https://doi.org/10.2165/00002512-200017050-00007
190 rdf:type schema:CreativeWork
191 sg:pub.10.2165/00002512-200118050-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044292364
192 https://doi.org/10.2165/00002512-200118050-00003
193 rdf:type schema:CreativeWork
194 sg:pub.10.2165/00003495-200060050-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003434116
195 https://doi.org/10.2165/00003495-200060050-00004
196 rdf:type schema:CreativeWork
197 sg:pub.10.2165/00003495-200262100-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012559787
198 https://doi.org/10.2165/00003495-200262100-00004
199 rdf:type schema:CreativeWork
200 sg:pub.10.2165/00003495-200363100-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050165822
201 https://doi.org/10.2165/00003495-200363100-00002
202 rdf:type schema:CreativeWork
203 sg:pub.10.2165/00003495-200464120-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005716893
204 https://doi.org/10.2165/00003495-200464120-00006
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1001/jama.281.21.2005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000047333
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1001/jama.287.19.2570 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023285132
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1001/jama.287.3.360 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045284159
211 rdf:type schema:CreativeWork
212 https://doi.org/10.1001/jama.290.4.486 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042599369
213 rdf:type schema:CreativeWork
214 https://doi.org/10.1016/j.amjmed.2003.08.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000975444
215 rdf:type schema:CreativeWork
216 https://doi.org/10.1016/j.amjmed.2003.10.017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051876972
217 rdf:type schema:CreativeWork
218 https://doi.org/10.1016/s0140-6736(00)90002-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031243451
219 rdf:type schema:CreativeWork
220 https://doi.org/10.1016/s0140-6736(01)06715-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014936450
221 rdf:type schema:CreativeWork
222 https://doi.org/10.1016/s0140-6736(02)08905-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040832542
223 rdf:type schema:CreativeWork
224 https://doi.org/10.1016/s0140-6736(98)07019-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018881858
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1016/s0140-6736(98)07037-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015697368
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1016/s0531-5131(02)01278-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023539162
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1016/s0735-1097(03)00916-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043406867
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1042/bst0300333 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031790720
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1046/j.1365-2125.1999.00030.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043231388
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1046/j.1463-1326.2000.00053.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1018580225
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1046/j.1463-1326.2002.00189.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019630371
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1046/j.1464-5491.1999.00023.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1049451052
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1046/j.1464-5491.1999.00166.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1001335743
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1046/j.1464-5491.2002.00734.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1033160698
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1056/nejm199602293340906 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031600279
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1056/nejmoa012512 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001036745
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1056/nejmoa021778 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018344641
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1056/nejmra041001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019925590
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1074/jbc.m106424200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045195003
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1074/jbc.r100034200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014264954
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1097/00041433-200312000-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003768084
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1111/j.1365-2362.2004.01381.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1025780657
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1136/bmj.321.7256.252 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048879453
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1136/bmj.321.7258.394 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052043497
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1136/bmj.325.7369.860 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002420008
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1136/bmj.327.7421.951 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002098315
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1152/ajpendo.1999.277.1.e1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074492025
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1161/01.cir.0000103683.99399.7e schema:sameAs https://app.dimensions.ai/details/publication/pub.1007027759
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1172/jci10762 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045265009
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1172/jci13505 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043705336
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1177/14746514030030051001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000069406
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1515/jpem.2002.15.s2.737 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049225232
281 rdf:type schema:CreativeWork
282 https://doi.org/10.2337/diab.21.9.976 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070732325
283 rdf:type schema:CreativeWork
284 https://doi.org/10.2337/diab.37.12.1595 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070735404
285 rdf:type schema:CreativeWork
286 https://doi.org/10.2337/diabetes.37.12.1595 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070741229
287 rdf:type schema:CreativeWork
288 https://doi.org/10.2337/diabetes.51.9.2796 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011011786
289 rdf:type schema:CreativeWork
290 https://doi.org/10.2337/diacare.15.6.737 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070745704
291 rdf:type schema:CreativeWork
292 https://doi.org/10.2337/diacare.16.1.184 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070745798
293 rdf:type schema:CreativeWork
294 https://doi.org/10.2337/diacare.20.6.925 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070747742
295 rdf:type schema:CreativeWork
296 https://doi.org/10.2337/diacare.22.6.960 schema:sameAs https://app.dimensions.ai/details/publication/pub.1070748809
297 rdf:type schema:CreativeWork
298 https://doi.org/10.2337/diacare.24.4.758 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035419921
299 rdf:type schema:CreativeWork
300 https://doi.org/10.2337/diacare.25.12.2244 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047089706
301 rdf:type schema:CreativeWork
302 https://doi.org/10.7326/0003-4819-131-4-199908170-00008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073703508
303 rdf:type schema:CreativeWork
304 https://doi.org/10.7326/0003-4819-134-1-200101020-00014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073704512
305 rdf:type schema:CreativeWork
306 https://doi.org/10.7326/0003-4819-137-1-200207020-00009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073705509
307 rdf:type schema:CreativeWork
308 https://doi.org/10.7861/clinmedicine.1-6-472 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003704904
309 rdf:type schema:CreativeWork
310 https://www.grid.ac/institutes/grid.430506.4 schema:alternateName University Hospital Southampton NHS Foundation Trust
311 schema:name Southampton University Hospitals NHS Trust, Southampton, UK
312 rdf:type schema:Organization
313 https://www.grid.ac/institutes/grid.7273.1 schema:alternateName Aston University
314 schema:name Life and Health Sciences, Aston Pharmacy School, Aston University, Birmingham, UK
315 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...